Tests rimegepant to prevent menstrual migraine in women
Tests rimegepant against placebo for preventing menstrual migraine attacks in women.
Plain-language title generated from the registry record
Registry title: A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Key facts
- Where
- Barcelona, Chiclana De La Frontera, Madrid, Santander, Sevilla, Valladolid, and Zaragoza, SpainSee the 9 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 45 with menstrual migraine. It tests rimegepant against placebo to prevent migraine around the period.
- Age
- 18 to 45 years
- Sex
- Women only
- Disease stage
- Migraine (with or without aura) for at least 1 year, and menstrual migraine attacks for at least 3 months. At least 1 migraine attack around the period in at least 2 of the last 3 cycles.
- Earlier treatment
- If taking a regular migraine preventive medicine, the dose must be stable for at least 3 months before screening and not expected to change during the study.
Main reasons for not taking part
- More than 6 migraine days per month outside the period in the 3 months before screening
- Chronic migraine, or more than 14 headache days per month on average in the 3 months before screening
- History of retinal, basilar or hemiplegic migraine
- Current schizophrenia, bipolar or borderline personality disorder
- Other pain syndromes (for example fibromyalgia) or significant neurological disorders other than migraine
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT06641466, who can take part
Where in Spain
- Hospital Clinic de BarcelonaBarcelona, SpainNo longer taking part
- Hospital Universitari Vall d'HebronBarcelona, SpainNo longer taking part
- Futuremeds Spain S.L.Chiclana De La Frontera, SpainNo longer taking part
- Hospital Universitario de la PrincesaMadrid, SpainNo longer taking part
- Hospital Universitario La PazMadrid, SpainNo longer taking part
- Hospital Universitario Marqués de ValdecillaSantander, SpainNo longer taking part
- University Hospital Virgen Del Rocio S.L.Sevilla, SpainNo longer taking part
- Hospital Clínico Universitario de ValladolidValladolid, SpainNo longer taking part
- Hospital Clinico Universitario Lozano BlesaZaragoza, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT06641466EU 2024-517121-10-00
- Record updated
- 9 July 2026
- Original description
The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.Read full original descriptionShow less
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE
The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
Inclusion: Participant has regular menstrual cycles ≥24 days and ≤34 days; A minimum 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition; A history of menstrual migraine attacks of at least 3 months; Participant reported history of experiencing at least 1 migraine attack during the perimenstrual period in at least 2 out of 3 menstrual cycles immediately prior to screening; If the participant is receiving a permitted background continuous prophylactic migraine medication, the medication dose must be stable for at least 3 months prior to the Screening visit and, the dose is not expected to change during the course of the study.
Exclusion: Greater than 6 migraine days per month that are outside of the perimenstrual period in the 3 months prior to Screening; A diagnosis of chronic migraine or a history of more than 14 headache days per month on average, in the 3 months prior to Screening; History of retinal migraine, basilar migraine or hemiplegic migraine; Current diagnosis of schizophrenia, bipolar, or borderline personality disorder; Other pain syndromes (eg, fibromyalgia, complex regional pain syndrome), or significant neurological disorders (other than migraine), or other medical conditions (including endocrine and gynecological eg, severe dysmenorrhea.